Vaccinex Total Stockholder Equity from 2010 to 2024

VCNX Stock  USD 3.69  0.13  3.65%   
Vaccinex Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity will likely drop to about -2.4 M in 2024. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2016-12-31
Previous Quarter
-2.9 M
Current Value
-1.3 M
Quarterly Volatility
30.8 M
 
Covid
Check Vaccinex financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaccinex's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 19.7 K or Depreciation And Amortization of 181 K, as well as many indicators such as Price To Sales Ratio of 7.19, Dividend Yield of 0.0 or Days Sales Outstanding of 451. Vaccinex financial statements analysis is a perfect complement when working with Vaccinex Valuation or Volatility modules.
  
Check out the analysis of Vaccinex Correlation against competitors.
For more information on how to buy Vaccinex Stock please use our How to Invest in Vaccinex guide.

Latest Vaccinex's Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Vaccinex over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Vaccinex's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaccinex's overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Very volatile
   Total Stockholder Equity   
       Timeline  

Vaccinex Total Stockholder Equity Regression Statistics

Arithmetic Mean(6,040,237)
Coefficient Of Variation(158.37)
Mean Deviation6,800,940
Median(3,329,000)
Standard Deviation9,565,658
Sample Variance91.5T
Range34M
R-Value(0.04)
Mean Square Error98.4T
R-Squared0
Significance0.89
Slope(81,596)
Total Sum of Squares1281T

Vaccinex Total Stockholder Equity History

2024-2.4 M
2023-2.3 M
20225.2 M
20217.4 M
2020-26.6 M
2019-26.2 M
2018-8.6 M

About Vaccinex Financial Statements

Vaccinex investors use historical fundamental indicators, such as Vaccinex's Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaccinex. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity-2.3 M-2.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaccinex Stock Analysis

When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.